Concepedia

Daniil Stroyakovskiy

DS

Statistics

Publications

79

Citations

22.3K

H-Index

48

Active since

2010

Affiliations

Moscow City Oncology Hospital №62(Current)

University of California, Los Angeles

Peter MacCallum Cancer Centre

Institut Gustave Roussy

The Maria Sklodowska-Curie National Research Institute of Oncology

Daniil Stroyakovskiy is an author at Moscow City Oncology Hospital №62 specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2010–2025

79

Publications

79

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

, , +16

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +16

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

, , +14

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

, , +7

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

, , +17

1–5 of 79